
CAS 1604810-83-4
:THZ1
Description:
THZ1, with the CAS number 1604810-83-4, is a small molecule that has garnered attention in the field of medicinal chemistry, particularly for its role as a selective inhibitor of the enzyme CDK7 (cyclin-dependent kinase 7). This compound is characterized by its ability to modulate transcriptional regulation and has potential implications in cancer therapy due to its influence on cell cycle progression and transcriptional control. THZ1 exhibits a unique structure that allows it to effectively bind to the ATP-binding site of CDK7, thereby inhibiting its activity. This inhibition can lead to a decrease in the phosphorylation of RNA polymerase II, ultimately affecting gene expression. Additionally, THZ1 has been studied for its selectivity and potency, making it a valuable tool in research aimed at understanding the role of CDK7 in various biological processes and diseases. Its development represents a significant advancement in targeted therapies, particularly in the context of oncology.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
Benzamide, N-[3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-4-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-
CAS:Formula:C31H28ClN7O2Purity:96%Color and Shape:SolidMolecular weight:566.0527THZ1
CAS:<p>THZ1 (CDK7 inhibitor) is a selective inhibitor of CDK7, binding to the Cys residue located at the outer end of the classical kinase domain. Cost-effective and quality-assured.</p>Formula:C31H28ClN7O2Purity:95.09% - 99.27%Color and Shape:SolidMolecular weight:566.05THZ1
CAS:<p>THZ1 is a kinase inhibitor that inhibits the activity of cyclin-dependent kinases. It has been shown to induce apoptosis in cancer cells and inhibit tumor growth. THZ1 also inhibits breast cancer cell proliferation, which may be due to its ability to inhibit cell cycle progression by blocking transcriptional and translational activities.</p>Formula:C31H28ClN7O2Purity:Min. 95%Molecular weight:566.05 g/mol




